Table 2.

Overview of Planned and Ongoing Ketamine for Depression Studies Listed on ClinicalTrials.gov

	Patients		Ketamine Treatment					Outcome Measures
	Psychiatric Diagnosis	TRD	Delivery method	Dose	Formulation	Placebo	No. of Administrations	Antidepressant Effects	Other
Open Label Investigations
Yale University/New Haven Hospital	“Depression”	Not required	IV 1–2 min	.2 mg/kg	Racemic	—	1	MADRS	Suicide ideation
University Hospital Geneva	MDD	≥2 unsuccessful medication trials	IV	.5 mg/kg	Racemic	—	1	MADRS	Adverse events Brain function
Controlled Trials
Baylor College of Medicine/Mount Sinal School of Medicine	MDD	≥3 failed ATHF trials	IV 40 min	.5 mg/kg	Racemic	Midazolam (parallel arm)	1	MADRS QIDSa	Adverse eventsa Brain functiona Neuropsychological functiona
Mount Sinai School of Medicine	MDD	≥1 failed ATHF trial	IN	≤50 mg	Racemic	Saline (randomized order)	1	MADRS	Adverse events
AstraZenica/University of Manchester/University of Oxford	MDD	Not required	IV	Unknown	Racemic	Saline (parallel arm)	1	MADRS	Brain function Behavioral tasks Pharmacokinetics
Washington University School of Medicine/University of Miami	MDD	“at PI discretion”	IV	.27 mg/kg + .00225 mg/kg/min	Racemic	Saline (randomized order)	2 (with gabapentin or placebo PO before infusion)	HDRS	Adverse events
National Institutes of Mental Health (substudy 4)	MDD or BD	≥1 failed ATHF trial	IV	Unknown	Racemic	Saline (randomized order)	1	Unknown	Brain function
University of New South Wales/Northside Clinic Wesley Hospitals	MDD or BD	Not required	IV	.1–.4 mg/kg	Racemic	Saline (parallel arm)	Up to 8 (weekly)	Unknown	Psychiatric symptoms Dissociative symptoms Cognitive impairment
Juvenile Bipolar Research Foundation	BD	Yes	IN	10–20 mg	Racemic	Flat tonic water (parallel arm)	4	Unknown	Aggression Manic symptoms OCD symptoms
Ketamine During ECT
Massachusetts General Hospital	MDD	Yes (ECT eligible)	IV	.5 mg/kg	Racemic	Saline (parallel arm)	3 (with ECT)	HDRS	Brain function Cognitive impairment
University of New South Wales/Northside Clinic Wesley Hospitals	MDD or BD	Yes (ECT eligible)	IV	.25–.5 mg/kg	Racemic	Saline (parallel arm)	3–6 (with ECT)	Depression rating scales	Cognitive impairment
Mayo Clinic	“Depression”	Yes (ECT eligible)	Unknown	Unknown	Racemic	Methohexital (parallel arm)	Several (with ECT)	“Hospital Anxiety and Depression Scale”	Unknown
University of Aberdeen/Royal Carnhill Hospital	“Depression”	Yes (ECT eligible)	IV	Unknown	Racemic	Propofol (parallel arm)	At least 4 (with ECT)	HDRS MADRS	Cognitive impairment

For all studies listed here, study status on ClinicalTrials.gov is “Completed,” “Enrolling by Invitation,” “Recruiting,” or “Not Yet Recruiting,” and results have not yet been published.

ATHF, Antidepressant Treatment History Form; BD, bipolar disorder; ECT, electroconvulsive therapy; HDRS, Hamilton Depression Rating Scale; IN, intranasal; IV, intravenous; MADRS, Montgomery-Åsberg Depression Rating Scale; MDD, major depressive disorder; OCD, obsessive-compulsive disorder; PO, per oral; QIDS, Quick Inventory of Depressive Symptoms; TRD, treatment-resistant depression.

^aInformation available from study investigators.